Recent Advances in Clinically Used and Trialed Photosensitizers for Antitumor Photodynamic Therapy.

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Liyun Chen, Yuxin Lin, Shangli Ding, Mingdong Huang, Longguang Jiang
{"title":"Recent Advances in Clinically Used and Trialed Photosensitizers for Antitumor Photodynamic Therapy.","authors":"Liyun Chen, Yuxin Lin, Shangli Ding, Mingdong Huang, Longguang Jiang","doi":"10.1021/acs.molpharmaceut.5c00110","DOIUrl":null,"url":null,"abstract":"<p><p>Photodynamic therapy (PDT) has gained significant attention as a minimally invasive cancer treatment that induces localized cytotoxicity with limited systemic side effects. When activated by light, typically in the visible or near-infrared spectrum, photosensitizers generate reactive oxygen species (ROS), leading to direct tumor cell death, vascular disruption, and stimulation of antitumor immune responses. This review provides an in-depth overview of the current understanding of PDT's antitumor mechanisms, focusing on ROS-induced cell death, immunogenic cell death, and tumor microenvironment modulation. Additionally, this review provides a critical evaluation of both clinically approved and investigational photosensitizers, detailing their chemical structures, photophysical properties, and therapeutic applications. We also discuss recent advances in combination strategies that integrate PDT with chemotherapy, radiotherapy, or immunotherapy to achieve enhanced therapeutic outcomes. Special emphasis is placed on emerging smart photosensitizers and tumor-targeted delivery systems that respond to microenvironmental stimuli, enhancing therapeutic precision and efficacy.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.5c00110","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Photodynamic therapy (PDT) has gained significant attention as a minimally invasive cancer treatment that induces localized cytotoxicity with limited systemic side effects. When activated by light, typically in the visible or near-infrared spectrum, photosensitizers generate reactive oxygen species (ROS), leading to direct tumor cell death, vascular disruption, and stimulation of antitumor immune responses. This review provides an in-depth overview of the current understanding of PDT's antitumor mechanisms, focusing on ROS-induced cell death, immunogenic cell death, and tumor microenvironment modulation. Additionally, this review provides a critical evaluation of both clinically approved and investigational photosensitizers, detailing their chemical structures, photophysical properties, and therapeutic applications. We also discuss recent advances in combination strategies that integrate PDT with chemotherapy, radiotherapy, or immunotherapy to achieve enhanced therapeutic outcomes. Special emphasis is placed on emerging smart photosensitizers and tumor-targeted delivery systems that respond to microenvironmental stimuli, enhancing therapeutic precision and efficacy.

抗肿瘤光动力治疗中光敏剂的临床应用和试验进展。
光动力疗法(PDT)作为一种可诱导局部细胞毒性且全身副作用有限的微创癌症治疗方法,受到了广泛关注。当被光激活时,通常在可见光或近红外光谱下,光敏剂产生活性氧(ROS),直接导致肿瘤细胞死亡、血管破坏和刺激抗肿瘤免疫反应。本文综述了目前对PDT抗肿瘤机制的深入了解,重点介绍了ros诱导的细胞死亡、免疫原性细胞死亡和肿瘤微环境调节。此外,这篇综述提供了临床批准和研究中的光敏剂的关键评估,详细介绍了它们的化学结构、光物理性质和治疗应用。我们还讨论了将PDT与化疗、放疗或免疫治疗相结合以提高治疗效果的联合策略的最新进展。特别强调的是新兴的智能光敏剂和肿瘤靶向递送系统,它们响应微环境刺激,提高治疗精度和疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信